- 专利标题: Polyspecific Binding Molecules and their use in Cell Therapy
-
申请号: US17996589申请日: 2021-04-21
-
公开(公告)号: US20230201258A1公开(公告)日: 2023-06-29
- 发明人: Chengfei Pu , Lei Xiao , Jingrui Liu , Junkai Peng , Le Tian , Xiaogang Shen , Zhiyuan Cao , Zhao Wu
- 申请人: Innovative Cellular Therapeutics Holdings, Ltd. , Innovative Cellular Therapeutics, Inc.
- 申请人地址: US MD Rockville
- 专利权人: Innovative Cellular Therapeutics Holdings, Ltd.,Innovative Cellular Therapeutics, Inc.
- 当前专利权人: Innovative Cellular Therapeutics Holdings, Ltd.,Innovative Cellular Therapeutics, Inc.
- 当前专利权人地址: US MD Rockville; US MD Rockville
- 国际申请: PCT/US2021/028429 2021.04.21
- 进入国家日期: 2022-10-19
- 主分类号: A61K35/17
- IPC分类号: A61K35/17 ; A61P35/00 ; A61K39/395
摘要:
The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.
信息查询
IPC分类: